{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:39:54Z","timestamp":1786984794760,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.arcmed.2023.102910","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T23:49:06Z","timestamp":1700351346000},"page":"102910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9801-0458","authenticated-orcid":false,"given":"Ross","family":"Hamblin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-0643","authenticated-orcid":false,"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2023.102910_bib0001","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-Tumor Endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2023.102910_bib0002","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and Management of Pituitary Adenomas: A Review","volume":"329","author":"Tritos","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2023.102910_bib0003","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102910_bib0004","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.arcmed.2023.102910_bib0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0006","doi-asserted-by":"crossref","first-page":"D11","DOI":"10.1530\/EJE-21-0344","article-title":"Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma","volume":"185","author":"Greenman","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0007","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ijnp\/pyac031","article-title":"Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System","volume":"25","author":"Fusaroli","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0008","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.arcmed.2023.102910_bib0009","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013"},{"key":"10.1016\/j.arcmed.2023.102910_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/appi.ajp.2018.18040465","article-title":"Impulse Control Disorders in Parkinson's Disease","volume":"176","author":"Weintraub","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.arcmed.2023.102910_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mdc3.13128","article-title":"Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review","volume":"8","author":"Parra-Diaz","year":"2021","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.arcmed.2023.102910_bib0012","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102910_bib0013","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0014","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","article-title":"Parkinson's Progression Markers I. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study","volume":"80","author":"Weintraub","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.arcmed.2023.102910_bib0015","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s00415-021-10724-1","article-title":"Risk factors of impulsive-compulsive behaviors in PD patients: a meta\u2013analysis","volume":"269","author":"Cao","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0016","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mds.27668","article-title":"Impulse control disorders in Parkinson's disease: A 20-year odyssey","volume":"34","author":"Weintraub","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.arcmed.2023.102910_bib0017","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10899-009-9123-2","article-title":"Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia","volume":"25","author":"Holman","year":"2009","journal-title":"J Gambl Stud"},{"key":"10.1016\/j.arcmed.2023.102910_bib0018","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","article-title":"Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome","volume":"30","author":"Driver-Dunckley","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0019","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.2.5916.419","article-title":"Long-term treatment of galactorrhoea and hypogonadism with bromocriptine","volume":"2","author":"Thorner","year":"1974","journal-title":"Br Med J"},{"key":"10.1016\/j.arcmed.2023.102910_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","article-title":"Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma","volume":"19","author":"Davie","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.arcmed.2023.102910_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0022","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102910_bib0023","doi-asserted-by":"crossref","first-page":"dgz076","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102910_bib0024","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","article-title":"The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study","volume":"22","author":"Ke","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.arcmed.2023.102910_bib0025","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102910_bib0026","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1210\/clinem\/dgac718","article-title":"A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma","volume":"108","author":"Sahin","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102910_bib0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0028-3886.370452","article-title":"Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature","volume":"71","author":"Sanjan","year":"2023","journal-title":"Neurol India"},{"key":"10.1016\/j.arcmed.2023.102910_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.579606","article-title":"Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas","volume":"11","author":"Hinojosa-Amaya","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2023.102910_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101356","article-title":"Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas","volume":"55","author":"Ozkaya","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.arcmed.2023.102910_bib0030","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102910_bib0031","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/EJE-21-0293","article-title":"Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study","volume":"185","author":"Baussart","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0032","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-16-0087","article-title":"THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature","volume":"175","author":"Tampourlou","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0033","unstructured":"Hamblin R, Karavitaki N. Prevalence of impulse control disorders in patients with prolactinomas or acromegaly: A systematic review and meta-analysis. PROSPERO 2022 CRD42022368025 Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022368025. (Accessed July 2, 2023)."},{"key":"10.1016\/j.arcmed.2023.102910_bib0034","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.arcmed.2023.102910_bib0035","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","article-title":"Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement","volume":"65","author":"Hoy","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0036","unstructured":"Wells GA, Shea B, O'Connell D, et\u00a0al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute 2000. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. (Accessed July 2, 2023)."},{"key":"10.1016\/j.arcmed.2023.102910_bib0037","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","article-title":"Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study","volume":"44","author":"Beccuti","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102910_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNN.0000000000000320","article-title":"Effect of Dopaminergic Therapy on Impulse Control Disorders in Patients With a Prolactinoma","volume":"36","author":"Ozdeniz Varan","year":"2023","journal-title":"Cogn Behav Neurol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0039","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102910_bib0040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102910_bib0041","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1176\/appi.ajp.162.11.2184","article-title":"Impulse control disorders in adult psychiatric inpatients","volume":"162","author":"Grant","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.arcmed.2023.102910_bib0042","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.psychres.2018.05.006","article-title":"Minnesota Impulse Disorders Interview (MIDI): Validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample","volume":"265","author":"Chamberlain","year":"2018","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.arcmed.2023.102910_bib0043","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.arcmed.2023.102910_bib0044","series-title":"The Oxford handbook of impulse control disorders","author":"Grant","year":"2011"},{"key":"10.1016\/j.arcmed.2023.102910_bib0045","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1176\/ajp.144.9.1184","article-title":"The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers","volume":"144","author":"Lesieur","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.arcmed.2023.102910_bib0046","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome","volume":"19","author":"Evans","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.arcmed.2023.102910_bib0047","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1212\/01.wnl.0000238503.20816.13","article-title":"Prevalence of repetitive and reward-seeking behaviors in Parkinson disease","volume":"67","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.arcmed.2023.102910_bib0048","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/mds.27689","article-title":"Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations","volume":"34","author":"Evans","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.arcmed.2023.102910_bib0049","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.parkreldis.2010.11.015","article-title":"Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability","volume":"17","author":"Papay","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.arcmed.2023.102910_bib0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000335996","article-title":"Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls","volume":"96","author":"Athanasoulia","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102910_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2021.101439","article-title":"Personality traits in acromegalic patients: Comparison with patients with non-functioning adenomas and healthy controls","volume":"62","author":"Kan","year":"2022","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.arcmed.2023.102910_bib0052","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EJE-08-0896","article-title":"Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls","volume":"160","author":"Sievers","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102910_bib0053","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rbp.2012.03.001","article-title":"Lifetime Prevalence, age and gender distribution and age-of-onset of psychiatric disorders in the Sao Paulo Metropolitan Area, Brazil: results from the Sao Paulo Megacity Mental Health Survey","volume":"34","author":"Viana","year":"2012","journal-title":"Braz J Psychiatry"},{"key":"10.1016\/j.arcmed.2023.102910_bib0054","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","article-title":"Prospective cohort study of impulse control disorders in Parkinson's disease","volume":"28","author":"Bastiaens","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.arcmed.2023.102910_bib0055","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EO-21-0038","article-title":"Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?","volume":"2","author":"De Sousa","year":"2022","journal-title":"Endocr Oncol"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T09:14:37Z","timestamp":1741166077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440923001480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0188440923001480"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102910","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102910"}}